NovaBridge Biosciences (NBP) EBIT (2019 - 2025)
NovaBridge Biosciences (NBP) posted quarterly EBIT of -$72.9 million for Q4 2025, down 445.21% year-over-year from $21.1 million in Q4 2024, and down 710.99% quarter-over-quarter from -$9.0 million in Q3 2025.
Powered by 
Analysis
NovaBridge Biosciences (NBP) EBIT (2019 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has reported EBIT for 5 consecutive years, with -$72.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, EBIT fell 445.21% year-over-year to -$72.9 million; the TTM figure through Dec 2025 stood at -$94.3 million (down 83.31% YoY), while the FY2025 annual figure was -$94.3 million, down 83.31% from the prior year.
- EBIT retreated to -$72.9 million in Q4 2025 per NBP's latest filing, from -$9.0 million in the prior quarter.
- Across five years, EBIT topped out at -$5.3 million in Q1 2025 and bottomed at -$72.9 million in Q4 2025.
- Historically, EBIT has averaged -$18.9 million across 3 years, with a median of -$12.0 million in 2023.
- Annual changes were most pronounced in 2024 — EBIT jumped 66.12% — and 2025, when it slumped 445.21%.
- NovaBridge Biosciences' EBIT stood at -$39.5 million in 2023, then surged by 66.12% to -$13.4 million in 2024, then plunged by 445.21% to -$72.9 million in 2025.
- Business Quant data shows NBP's EBIT at -$72.9 million in Q4 2025, -$9.0 million in Q3 2025, and -$7.1 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -1.55 Mn |
| 10 | NovaBridge Biosciences | 199.33 Mn | 199.33 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -72.90 Mn |
| Sep 30, 2025 | -8.99 Mn |
| Jun 30, 2025 | -7.11 Mn |
| Mar 31, 2025 | -5.27 Mn |
| Dec 31, 2024 | -13.37 Mn |
| Sep 30, 2024 | -12.41 Mn |
| Jun 30, 2024 | -17.14 Mn |
| Mar 31, 2024 | -8.50 Mn |
| Dec 31, 2023 | -39.46 Mn |
| Sep 30, 2023 | -10.63 Mn |
| Jun 30, 2023 | -12.05 Mn |
| Dec 31, 2020 | 175.76 Mn |
| Sep 30, 2020 | -57.15 Mn |
| Dec 31, 2019 | -47.37 Mn |
| Sep 30, 2019 | -43.72 Mn |